Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain scans may reveal Alzheimer's years before symptoms

NCT ID NCT01638949

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study used brain imaging and memory tests to find early signs of Alzheimer's disease. Researchers followed 242 volunteers, including healthy young, middle-aged, and older adults, to track changes over time. The goal was to understand how the disease develops and identify markers that could lead to earlier diagnosis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help identify early markers for Alzheimer's, potentially leading to earlier diagnosis and better monitoring of the disease.
What could go wrong
This is an observational study, not a treatment trial. It may not directly lead to new therapies, and findings may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

242 people

The number who actually took part.

Started

May 2012

Finished

Sep 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria : * Education level \> 7 years * Native language: French * Medical, neurological, neuropsychological and neuroradiological depth in accordance with the criteria for inclusion and exclusion-specific population, that is to say: * Healthy young volunteers: between 18 and 40 years old; normal performances compared to the age and the educational level for all tests of the diagnostic battery (± 1.65 SD). * Healthy Middle-aged volunteers: between 40 and 60 years old; without memory complaints, normal performances compared to the age and the educational level for all tests of the diagnostic battery (± 1.65 SD). * Healthy Elderly volunteers: over 60 years old, living at home, without memory complaints, normal performances compared to the age and the educational level for all tests of the diagnostic battery (± 1.65 SD). * SCI patients: over 60 years old ; memory complaints; memory complaint ; normal performances compared to the age and the educational level for all tests of the diagnostic battery (± 1.65 SD). * MCI patients: presenting the current criteria for amnestic MCI including: i) memory complaint, ii) deficits of the episodic memory (lower performance of at least 1.65 SD from the norm for age and cultural level for one or more scores of episodic memory and iii) normal performances compared to the age and the educational level of all other cognitive functions as memory, including tests to assess cognitive abilities. * Alzheimer's patients: presenting the standard criteria of NINCDS-ADRDA probable Alzheimer's disease, including abnormal global cognitive function and deficits in at least two cognitive domains identified by the diagnostic battery and a mild to moderate Alzheimer's disease (MMSE ≥ 15). Exclusion Criteria : * The sudden onset of cognitive impairments (as opposed to their slow and gradual installation in Alzheimer's disease) * A chronic neurological, psychiatric, endocrine, hepatic or infectious complaint * A history of major disease (an uncontrolled diabetes, a lung, heart, metabolic, hematologic, endocrine disease or a severe cancer) * A medication that may interfere with memory or metabolic measures * A alcohol or drugs abuse * The cons-indications to MRI (claustrophobia, metallic object in the body) * A predominantly left-hand (score below 50% in Edinburgh Inventory) * Protected adults, and persons not affiliated with a social security system will not participate in this study * The inclusion of a participant in another biomedical research protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer's disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • GIP Cyceron

    Caen, Calvados, 14000, France

  • Inserm - EPHE - University of Caen U1077

    Caen, 14000, France

  • University Hospital Côte de Nacre

    Caen, 14033, France

  • University Hospital Pontchaillou

    Rennes, 35033, France

  • University Hospital Roger Salengro

    Lille, 59037, France

  • University Hospital Rouen

    Rouen, 76031, France

  • University Hospital Tours

    Tours, 37044, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.